Literature DB >> 23173725

Model systems for rapid and slow induction of apoptosis obtained by inducible expression of pro-apoptotic proteins.

Christian Maueröder1, Ricardo A Chaurio, Stephanie Platzer, Luis E Muñoz, Christian Berens.   

Abstract

Killing tumor cells is a central goal of non-surgical cancer therapy and induction of apoptosis in the malignant cells is the major strategy used to achieve it. However, this may have serious drawbacks, since apoptotic cells reportedly induce immunological tumor tolerance and activate a tumor repopulation program. The debate on which type of cell death has the most beneficial therapeutic effects in cancer treatment is intense and controversial. Stringently regulated, doxycycline-inducible transgene expression systems trigger cell death in a defined manner, which might help us find answers to these problems. A conditional suicide switch established transiently in Jurkat T-cells was used to test a set of pro-apoptotic proteins for their potency to induce cell death. The activated forms of caspase-3 (revCasp-3) and Bid (tBid) were very effective and, therefore, analyzed after stable integration into human leukemia and murine melanoma cell lines. Expression of either protein resulted in more than 95% cell death, but with strongly different kinetics. 85% cell death was observed if tBid and revCasp-3 were expressed for 4-6 hours and 18-24 hours, respectively. The human cell lines expressing these suicide switches can serve as cancer models in xeno-transplanted mice, the corresponding murine cell lines allow syngeneic and allogeneic murine cancer models to be established.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23173725     DOI: 10.3109/08916934.2012.752463

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  7 in total

1.  Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling.

Authors:  Christian Berens; Stephanie Bisle; Leonie Klingenbeck; Anja Lührmann
Journal:  J Vis Exp       Date:  2015-06-25       Impact factor: 1.355

2.  A blast without power - cell death induced by the tuberculosis-necrotizing toxin fails to elicit adequate immune responses.

Authors:  C Maueröder; R A Chaurio; T Dumych; M Podolska; M D Lootsik; S Culemann; R P Friedrich; R Bilyy; C Alexiou; G Schett; C Berens; M Herrmann; L E Munoz
Journal:  Cell Death Differ       Date:  2016-03-04       Impact factor: 15.828

3.  Irradiation-Induced Changes in the Immunogenicity of Lung Cancer Cell Lines: Based on Comparison of X-rays and Carbon Ions.

Authors:  Juntao Ran; Jiangtao Wang; Ziying Dai; Yandong Miao; Jian Gan; Chengpeng Zhao; Quanlin Guan
Journal:  Front Public Health       Date:  2021-04-22

Review 4.  Tumor immunotherapy: lessons from autoimmunity.

Authors:  Christian Maueröder; Luis Enrique Munoz; Ricardo Alfredo Chaurio; Martin Herrmann; Georg Schett; Christian Berens
Journal:  Front Immunol       Date:  2014-05-13       Impact factor: 7.561

5.  The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy.

Authors:  Ricardo A Chaurio; Luis E Muñoz; Christian Maueröder; Christina Janko; Thomas Harrer; Barbara G Fürnrohr; Michael Niederweis; Rostyslav Bilyy; Georg Schett; Martin Herrmann; Christian Berens
Journal:  Front Immunol       Date:  2014-11-11       Impact factor: 7.561

6.  tLivin displays flexibility by promoting alternative cell death mechanisms.

Authors:  Tamar Shiloach; Christian Berens; Christina Danke; Ortal Waiskopf; Riki Perlman; Dina Ben-Yehuda
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

7.  Apoptotic stress induces Bax-dependent, caspase-independent redistribution of LINC complex nesprins.

Authors:  Liora Lindenboim; Dan Grozki; Ayelet R Amsalem-Zafran; Aida Peña-Blanco; Gregg G Gundersen; Christoph Borner; Didier Hodzic; Ana J Garcia-Sáez; Howard J Worman; Reuven Stein
Journal:  Cell Death Discov       Date:  2020-09-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.